Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The data, presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), shows patients report TYSABRI has an impact in improving their overall quality of life.
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
"The symptoms that an MS patient deals with on a daily basis result in significant psychological and physical effects that can adversely impact their quality of life," said William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "In a previous pivotal trial, TYSABRI not only showed a reduction in relapse rates and disability progression, but also improved quality of life. Results from this observational study further demonstrate the impact of TYSABRI on improving MS patients' well-being as reported by patients who live with this disease every day."
About the studyThe study is assessing health outcomes from patients' perspectives before starting TYSABRI and after the third, sixth and 12th infusions of TYSABRI. A majority of the patients in the study are female (76.3%) with mean age of 46.6 years and mean disease duration of 10 years.
![Fewer Injection Site Reactions in Patients Using Avonex]( "Fewer Injection Site Reactions in Patients Using Avonex")
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX...
After six TYSABRI infusions, patients reported statistically significant improvement in:
Both scales assess patient experience of the physical and psychological aspects of QoL. For the MSIS-29 subscales, there were statistically significant improvements over time for both the physical (baseline 46.87; third infusion 39.60; sixth infusion 39.27 (p< 0.001)) and psychological (baseline 41.56; third infusion 33.77; sixth infusion 33.20 (p< 0.001)) impact scores.
SF-12 physical component summary (baseline 34.20; third infusion 36.05; sixth infusion 36.34 (p< 0.001)) and the SF-12 mental component summary score (baseline 43.25, third infusion 47.35, sixth infusion 47.92 (p< 0.001)) showed statistically significant improvements over time.
What do multiple sclerosis patients experience? Effect of natalizumab on disease-specific quality of life over time (poster P872).
Source: Eurekalert
LIN
Fewer Injection Site Reactions in Patients Using Avonex
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX...
Advertisement
After six TYSABRI infusions, patients reported statistically significant improvement in:
- Disease-specific quality of life (QoL), as measured by the Multiple Sclerosis Impact Scale-29 (MSIS-29), which measures the physical impact of MS in terms of mobility and self care, as well as the psychological impact of MS in terms of anxiety/depression, with lower scores indicating better QoL; and
- General health-related QoL, as measured by the 12-item Short Form Scale (SF-12) health survey, which assesses the physical and mental health, with higher scores indicating better QoL.
Both scales assess patient experience of the physical and psychological aspects of QoL. For the MSIS-29 subscales, there were statistically significant improvements over time for both the physical (baseline 46.87; third infusion 39.60; sixth infusion 39.27 (p< 0.001)) and psychological (baseline 41.56; third infusion 33.77; sixth infusion 33.20 (p< 0.001)) impact scores.
SF-12 physical component summary (baseline 34.20; third infusion 36.05; sixth infusion 36.34 (p< 0.001)) and the SF-12 mental component summary score (baseline 43.25, third infusion 47.35, sixth infusion 47.92 (p< 0.001)) showed statistically significant improvements over time.
What do multiple sclerosis patients experience? Effect of natalizumab on disease-specific quality of life over time (poster P872).
Source: Eurekalert
LIN
Researchers Identify Genes as Potential Therapeutic Targets for Multiple Sclerosis
A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS).
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.